155 Results

People

  1. Perales
    Perales
  2. Brentjens
    Brentjens
  3. Park
    Park
  4. Palomba
    Palomba
  5. Sadelain
    Sadelain
  6. Shah
    Shah
  7. Shouval
    Shouval
  8. Riviere
    Riviere
  9. Dahi
    Dahi
  10. Salles
    Salles

Groups

  1. Department of Medicine (122)
  2. Hematologic Malignancies, Division of (122)
  3. Center for Hematologic Malignancies (115)
  4. GSK Faculty (64)
  5. Adult Leukemia (52)
  6. Hematologic Malignancies Research (51)
  7. Sloan Kettering Institute Faculty (44)
  8. Bone Marrow Transplant (41)
  9. Molecular Pharmacology and Chemistry Program Faculty (38)
  10. Sloan Kettering Institute Postdocs (31)
  1. "cd19 antigen"
Formats
  1. Journal Article (117)
  2. Review (25)
  3. Research Letter (5)
  4. Correspondence (4)
  5. Editorial (2)
  6. Guidelines (1)
  7. Miscellaneous (1)
Groups
  1. Department of Medicine (122)
  2. Hematologic Malignancies, Division of (122)
  3. Center for Hematologic Malignancies (115)
  4. GSK Faculty (64)
  5. Adult Leukemia (52)
  6. Hematologic Malignancies Research (51)

More Groups

People
  1. Michel Sadelain (32)
  2. Miguel-Angel Perales (32)
  3. Renier Brentjens (28)
  4. Jae Park (26)
  5. Gunjan Shah (17)
  6. Maria Palomba (17)

More People

Years
  1. 2025 (11)
  2. 2024 (14)
  3. 2023 (28)
  4. 2022 (21)
  5. 2021 (5)
  6. 2020 (12)

More Years

Publications
  1. Transplantation and Cellular Therapy (14)
  2. Blood (13)
  3. Leukemia and Lymphoma (10)
  4. Clinical Cancer Research (5)
  5. Leukemia (5)
  6. Journal of Clinical Oncology (4)

More Publications

Publishers
  1. Nature Publishing Group (29)
  2. Elsevier Inc. (23)
  3. American Society of Hematology (18)
  4. Taylor & Francis Group (12)
  5. American Association for Cancer Research (8)
  6. American Society of Clinical Oncology (6)

More Publishers

Results (155)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: A review
    Review

    Locatelli, F.; Shah, B.; Thomas, T.; Velasco, K.; Adedokun, B.; Aldoss, I.; Gore, L.; Hoelzer, D.; Bassan, R.; Park, J. H.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma
    Guidelines

    Epperla, N.; Kumar, A.; Abutalib, S. A.; Awan, F. T.; Chen, Y. B.; Gopal, A. K.; Holter-Chakrabarty, J.; Kekre, N.; Lee, C. J.; Lekakis, L.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
    Journal Article

    Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy
    Journal Article

    Gao, Q.; Liu, Y.; Aypar, U.; Baik, J.; Londono, D.; Sun, X.; Zhang, J.; Zhang, Y.; Roshal, M.
    Cytometry Part B—Clinical Cytometry (2023)

    Fulltext@MSK | Save
  • Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
    Journal Article

    Wudhikarn, K.; Tomas, A. A.; Flynn, J. R.; Devlin, S. M.; Brower, J.; Bachanova, V.; Nastoupil, L. J.; McGuirk, J. P.; Maziarz, R. T.; Oluwole, O. O.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma
    Review

    Ahmed, N.; Wesson, W.; Mushtaq, M. U.; Porter, D. L.; Nasta, S. D.; Brower, J.; Bachanova, V.; Hu, M.; Nastoupil, L. J.; Oluwole, O. O.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Survival with axicabtagene ciloleucel in large B-cell lymphoma
    Journal Article

    Westin, J. R.; Oluwole, O. O.; Kersten, M. J.; Miklos, D. B.; Perales, M. A.; Ghobadi, A.; Rapoport, A. P.; Sureda, A.; Jacobson, C. A.; Farooq, U.; more...
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results
    Journal Article

    Park, J. H.; Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G.; Dahi, P.; Lin, R. J.; Scordo, M.; Perales, M. A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Journal Article

    Roddie, C.; Lekakis, L. J.; Marzolini, M. A. V.; Ramakrishnan, A.; Zhang, Y.; Hu, Y.; Peddareddigari, V. G. R.; Khokhar, N.; Chen, R.; Basilico, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma
    Journal Article

    Westin, J. R.; Locke, F. L.; Dickinson, M.; Ghobadi, A.; Elsawy, M.; van Meerten, T.; Miklos, D. B.; Ulrickson, M. L.; Perales, M. A.; Farooq, U.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save